Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Latest news

Group By Ticker
Sort By
Newest | Oldest
Read More
3 minute read
  • Commodities
  • Earnings
  • Eurozone
  • Global
  • Intraday Update
  • Markets
  • News
  • Penny Stocks

Nasdaq Jumps 200 Points; Baudax Bio Shares Spike Higher

By Lisa Levin
June 30, 2:34 PM
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 1% on Friday. The Dow traded up 0.93% to 34,439.75 while the NASDAQ rose 1.54% to 13,800.92. The S&P 500, also rose, gaining, 1.32% to 4,454.48.

BXRX

Read More
3 minute read
  • Movers

12 Health Care Stocks Moving In Friday’s Intraday Session

By Benzinga Insights
June 30, 1:37 PM
Gainers Baudax Bio (NASDAQ:BXRX) shares increased by 130.7% to $1.2 during Friday’s regular session. Trading volume for this…

APYX

Read More
3 minute read
  • Intraday Update
  • Markets
  • Movers
  • News
  • Penny Stocks
  • Small Cap
  • Trading Ideas

Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday’s Mid-Day Session

By Lisa Levin
June 30, 12:34 PM
Gainers Addentax Group Corp. (NASDAQ: ATXG) shares jumped 47.3% to $9.68. Addentax Group is launching automation of artificial intelligence internet operational tools project with top Games-as-a-Service firms.

AAOI

Read More
3 minute read
  • Commodities
  • Earnings
  • Eurozone
  • Global
  • Intraday Update
  • Markets
  • News
  • Penny Stocks
  • Trading Ideas

Crude Oil Rises Over 1%; Fed’s Preferred Inflation Gauge Slows In May

By Lisa Levin
June 30, 12:01 PM
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 1% on Friday. The Dow traded up 0.62% to 34,333.42 while the NASDAQ rose 1.37% to 13,777.52. The S&P 500, also rose, gaining, 1.04% to 4,441.95.

BXRX

Read More
1 minute read
  • Movers

12 Health Care Stocks Moving In Friday’s Pre-Market Session

By Benzinga Insights
June 30, 9:12 AM
Gainers Renalytix (NASDAQ:RNLX) shares moved upwards by 38.6% to $2.87 during Friday’s pre-market session. The company’s market cap…

ALVO

Read More
2 minute read
  • News

Cyteir Therapeutics Announces Discontinuation Of CYT-0851 Development Program And Planned Liquidation And Dissolution

By Happy Mohamed
June 30, 8:07 AM
Cyteir Therapeutics, Inc. ("Cyteir" or the "Company") (NASDAQ:CYT) today announced that it is discontinuing all development of CYT-0851, its investigational monocarboxylate transporter inhibitor, and

CYT

Read More
1 minute read
  • Analyst Ratings
  • Downgrades
  • News
  • Price Target

Morgan Stanley Downgrades Cyteir Therapeutics to Underweight, Lowers Price Target to $2

By Benzinga Newsdesk
February 3, 7:20 AM
Morgan Stanley analyst Jeffrey Hung downgrades Cyteir Therapeutics (NASDAQ:CYT) from Equal-Weight to Underweight and lowers the price target from $4 to $2.

CYT

Read More
1 minute read
  • Analyst Ratings
  • Downgrades
  • News
  • Price Target

B of A Securities Downgrades Cyteir Therapeutics to Neutral, Lowers Price Target to $2

By Benzinga Newsdesk
January 30, 8:17 AM
B of A Securities analyst Tazeen Ahmad downgrades Cyteir Therapeutics (NASDAQ:CYT) from Buy to Neutral and lowers the price target from $4 to $2.

CYT

Read More
1 minute read
  • Analyst Ratings
  • Downgrades
  • News

JP Morgan Downgrades Cyteir Therapeutics to Neutral

By Benzinga Newsdesk
January 20, 5:54 AM
JP Morgan analyst Anupam Rama downgrades Cyteir Therapeutics (NASDAQ:CYT) from Overweight to Neutral.

CYT

Read More
13 minute read
  • Options

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights
December 7, 12:38 PM
  Wednesday saw 219 companies set new 52-week lows.

$APE

Posts pagination

1 2 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service